Qingdao Novelbeam Technology Co.Ltd(688677) on January 10, it was announced that the company plans to establish a joint venture with China Medical Devices Co., Ltd. (hereinafter referred to as "Sinopharm devices"), Sinopharm group Yiguang Technology Co., Ltd. to take the complete medical endoscope system as the starting point, aim at China's medical endoscope market, establish its own brand, and build a leading enterprise in the field of domestic complete medical endoscope and minimally invasive surgery.
It is reported that the registered capital of the joint venture is 160 million yuan, of which Qingdao Novelbeam Technology Co.Ltd(688677) contributes 78.4 million yuan in currency, accounting for 49% of the total registered capital, and Sinopharm instruments contributes 81.6 million yuan in currency, accounting for 51% of the total registered capital. The joint venture will take the complete medical endoscope system as the starting point, aim at the Chinese medical endoscope market, establish its own brand, quickly achieve certification and sales, gradually occupy a certain market share in the Chinese market, and simultaneously start the R & D and iteration of the next generation of technologies and products, including 3D, artificial intelligence and other minimally invasive surgical technologies and products, Build a leading enterprise in the field of domestic medical endoscope and minimally invasive surgery.
The company said that the foreign investment to set up a subsidiary is based on the company's development strategy, gives full play to the advantages of the joint venture and partners, is conducive to resource sharing and common development, is conducive to improving the company's operating performance, and is in line with the company's future development strategy. The company is a leading technology-based company in the field of endoscope subdivision, with deep technical precipitation, product innovation ability, perfect production and manufacturing and quality control ability; Sinopharm is the strategic bearer of the medical device sector of Sinopharm group. It carries the mission of the professional development of medical devices in China. It has a wide range of medical institutional resources and clinical combination foundation, strong market capacity and sales channels. The cooperation between the company and Sinopharm is a strong cooperation between technology and clinic, products and market, with strong aggregation effect. The in-depth cooperation between the two sides is conducive to give full play to their respective strengths. On the one hand, they can fully combine technology and clinic, and develop truly clinical medical device products through continuous technical iteration; On the other hand, it can also organically combine high-quality products with market sales to quickly enlarge the market application and share of products.
In addition, the company's cooperation with Sinopharm instruments does not stop at endoscope products, but also creates a platform in the field of minimally invasive surgery to provide comprehensive products and services for surgical medicine.
(source: China Securities Journal · China Securities Network)
